Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2021 12:27 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; May 12, 2021 – Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
May 11, 2021 14:50 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; May 11, 2021 – Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this...
May 11, 2021 14:43 ET | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; May 11, 2021 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 33,418 shares as a consequence of the exercise of employee warrants. The...
May 10, 2021 03:55 ET | Source: Genmab A/S

Transactions in connection with share buy-back program

Company Announcement COPENHAGEN, Denmark; May 10, 2021 – Genmab A/S (Nasdaq: GMAB). On February 23, 2021 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant...
May 07, 2021 13:52 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; May 07, 2021 – Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this...
May 05, 2021 11:01 ET | Source: Genmab A/S

Genmab Announces Financial Results for the First Quarter of 2021

May 5, 2021; Copenhagen, Denmark; Genmab Interim Report for the First Quarter Ended March 31, 2021 Highlights Genmab and Seagen Inc. submitted tisotumab vedotin Biologics License Application...
May 03, 2021 14:58 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; May 03, 2021 – Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
May 03, 2021 03:47 ET | Source: Genmab A/S

Transactions in connection with share buy-back program

Company Announcement COPENHAGEN, Denmark; May 3, 2021 – Genmab A/S (Nasdaq: GMAB). On February 23, 2021 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant...
April 26, 2021 03:18 ET | Source: Genmab A/S

Transactions in connection with share buy-back program

Company Announcement COPENHAGEN, Denmark; April 26, 2021 – Genmab A/S (Nasdaq: GMAB). On February 23, 2021 Genmab announced the initiation of a share buy-back program to mitigate dilution from...
April 20, 2021 06:34 ET | Source: Genmab A/S

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2021

Company Announcement Net sales of DARZALEX® in the first quarter of 2021 totaled USD 1,365 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark;...